The William Harvey International Translational Research Academy (WHRI-ACADEMY) is a new fellowship programme which will maximise the career development of the next generation of translational multidisciplinary researchers geared towards innovation across rapidly developing life sciences and health care disciplines.
A large number of European and international universities and research institutes and industry and private partners have already enrolled as host organisations on the basis of their excellence in post doctoral training and development, outstanding infrastructure, high scientific prominence and high intensity of innovation activities. WHRI-ACADEMY programme is open to enrol additional host organisations.
WHRI-ACADEMY offers 55 new post-doc fellowships spread between three different schemes (incoming, outgoing and reintegration) and a training programme, including workshops, dedicated training in complementary skills and industrial placement.
WHRI-ACADEMY is open to applicants from all over the world. Applicants must, at the time of the recruitment by the Host Organization, be in possession of a doctoral degree, or have at least four years of full-time equivalent research experience.
WHRI-ACADEMY is centrally managed at the William Harvey Research Institute (WHRI). WHRI is a world leading Pharmacological Centre with a vibrant, multidisciplinary scientific environment devoted to therapeutic innovation in cardiovascular, endocrine and inflammatory diseases. WHRI is located at the picturesque Charterhouse Square campus of Queen Mary University of London.
WHRI-ACADEMY is coordinated by Professor Márta Korbonits.
WHRI-ACADEMY is a COFUND Marie Curie Actions (People programme). Its value is EUR 6.48 million, out of which 60% is financed from national sources.
Sicne its start, WHRI-ACADEMY has launched six Calls for Proposals for Experienced Researchers. Please note that we do not accept more applications.
WHRI-ACADEMY receives funding from the European Union's Seventh Framework Programme for research, technological development and demonstration activities under grant agreement no 608765.